Norwegian Institute of Public Health Has Recommended Stopping Use of AstraZeneca Vaccine (Vaxzevria)

“Higher Risk Associated with AstraZeneca Vaccine Than from COVID-19 Disease in Norway”

NIPH – Having come a long way in vaccinating the oldest citizens, Norway has reduced the risk of death for many of those most at risk. Since most of the elderly have either been vaccinated, or soon will be, this means that continued use of the vaccine would mainly be among the under-65 years age group if we were to use this vaccine in Norway.

Calculations have been performed based on Norwegian data where the risk of dying from COVID-19 disease among the different age groups is compared with the risk of dying from the severe, but rare, condition with severe blood clots observed after AstraZeneca vaccination.

“Since there are few people who die from COVID-19 in Norway, the risk of dying after vaccination with the AstraZeneca vaccine would be higher than the risk of dying from the disease, particularly for younger people,” says Bukholm.

In addition, there is reason to assume that there is scepticism about using the AstraZeneca vaccine in Norway, and it is uncertain how many people would have accepted an offer of this vaccine now.